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Abstract
Objective To estimate the cost effectiveness of vaccinating people with
high risk conditions against invasive pneumococcal disease using the
13 valent pneumococcal conjugate vaccine.
Design Economic evaluation using a cohort model from the perspective
of healthcare providers.
Setting England.
Participants People aged 2 years and older at increased risk of invasive
pneumococcal disease due to chronic kidney disease; splenic
dysfunction; HIV infection; a compromised immune system; chronic
heart, liver, or respiratory disease; or diabetes.
Main outcomemeasuresCosts, gains in life years and quality adjusted
life years (QALYs), and incremental cost effectiveness ratios.
Results Increasing indirect protection resulting from the vaccination
programme of infants using the 13 valent pneumococcal conjugate
vaccine means that the burden of disease preventable by targeting high
risk groups will diminish in time. Under base case assumptions—that
is, no overall impact on non bacteraemic pneumonia in high risk groups
and assuming the high risk vaccination programme would be launched
two to three years after the infant programme—the incremental cost
effectiveness ratio was estimated to be more than £30 000 (€37 216;
$48 210) per QALY gained for most risk groups. If, however, the vaccine
does not offer protection against non-bacteraemic pneumococcal
pneumonia or the vaccine was introduced concomitantly with the infant
13 valent pneumococcal conjugate vaccination programme then
vaccinating high risk people would (more) likely be cost effective.
Sensitivity analyses showed that the cost effectiveness was particularly
sensitive to assumed herd benefits and vaccine efficacy estimates.
Conclusion Under base case assumptions it is unlikely that a
pneumococcal vaccination programme aimed at risk groups could be
considered cost effective. Uncertainty could be substantially reduced by
establishing the effectiveness of the 13 valent pneumococcal conjugate
vaccine against non-bacteraemic pneumococcal pneumonia, particularly
in at risk groups.
Introduction
People with certain clinical conditions such as
immunocompromised patients and those with chronic heart or
lung disease are at increased risk of invasive pneumococcal
disease and related mortality.1 To prevent disease among these
high risk groups many countries recommend vaccination with
the 23 valent polysaccharide vaccine, which has been available
since the 1980s. Nevertheless, the efficacy and duration of
protection of this vaccine is limited, and the antibody response
to revaccination is reduced.2 3 The use of conjugated
pneumococcal vaccines could potentially overcome the
limitations of the 23 valent polysaccharide vaccine. In children
the seven valent pneumococcal conjugate vaccine has been
shown to be highly effective in preventing invasive
pneumococcal disease caused by vaccine related serotypes.4
Data on the efficacy in adults, elderly people, and high risk
groups are, however, scarce, with most studies focusing on
immunogenicity rather than on efficacy.3 The limited data on
efficacy that are available suggest that pneumococcal conjugate
Correspondence to: M Rozenbaum m.h.rozenbaum@rug.nl
Extra material as supplied by authors (see http://www.bmj.com/content/345/bmj.e6879?tab=related#webextra)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e6879 doi: 10.1136/bmj.e6879 (Published 26 October 2012) Page 1 of 17
Research
RESEARCH
 on 22 O












J: first published as 10.1136/bm





vaccines are effective in preventing invasive pneumococcal
disease (and possibly pneumonia) in adults and children infected
with HIV, a group in whom the 23 valent polysaccharide vaccine
is ineffective.5 6 As the pneumococcal conjugate vaccines are
more expensive, there is a need to assess whether the use of
these vaccines is justified. Such an assessment is complicated
by the interaction (at a population level) between a targeted risk
based programme and vaccination of children. The introduction
of seven valent pneumococcal conjugate vaccine in the infant
immunisation programme led to a dramatic decline in incidence
of invasive pneumococcal disease due to vaccine serotypes in
all age groups (including those in risk groups).7However, these
decreases were partly offset by a simultaneous increase in
disease caused by non-vaccine serotypes, reducing the impact
on overall invasive pneumococcal disease.8
In the infant programme in the United Kingdom, as elsewhere,
the seven valent pneumococcal conjugate vaccine has recently
been replaced by the 13 valent pneumococcal conjugate vaccine.
This higher valency vaccine covers six additional serotypes,
including the key replacement serotypes 19A and 7F. Similar
herd effects for the additional serotypes, as observed for the
seven serotypes included in the seven valent pneumococcal
conjugate vaccine after its implementation, can be expected in
time. However, high risk groups could potentially still benefit
from the faster and greater effects of direct vaccination with the
13 valent pneumococcal conjugate vaccine compared with
waiting for the indirect benefit from the herd immunity against
the vaccine serotypes generated by the infant programme.
We estimated the effectiveness, costs, and cost effectiveness of
vaccinating high risk groups in England using the 13 valent
pneumococcal conjugate vaccine, taking into account that herd
benefits of the current infant 13 valent pneumococcal conjugate
vaccine programme will diminish the potential impact of a
specific programme for high risk groups over time.
Methods
We estimated the costs, health benefits, and cost effectiveness
of vaccination of high risk groups with the 13 valent
pneumococcal conjugate vaccine on top of the current risk based
vaccination programme with the 23 valent polysaccharide
vaccine. This was done because the existing programme with
the 23 valent polysaccharide vaccine is likely be continued
despite the potential introduction of a risk based programme
using the 13 valent pneumococcal conjugate vaccine. In addition
our risk estimates for pneumococcal disease were estimated in
the current situation in which a risk based programme using the
23 valent polysaccharide vaccine is already in place (albeit with
a low uptake of vaccination).
As infants are already vaccinated with the 13 valent
pneumococcal conjugate vaccine, we restricted our analysis to
high risk patients aged 2 years and older. The perspective was
from that of the National Health Service, as recommended in
the United Kingdom.9
Model and population
Wedeveloped a cohort model to determine the cost effectiveness
of vaccinating specific high risk groups with the 13 valent
pneumococcal conjugate vaccine. Groups included in this
analysis were based on a recent study among patients admitted
to hospital in England with culture confirmed invasive
pneumococcal disease, which compared the prevalence of
clinical risk factors in the general population with that in patients
admitted to hospital with invasive pneumococcal disease.7 The
study sample comprised 22 298 patients admitted to hospital
between April 2002 and March 2009 with an admission record
in the hospital episode statistics database for England that could
be linked with the dataset of the national invasive pneumococcal
disease laboratory held at the Health Protection Agency.7
In the current analysis we differentiate between people who are
immunocompromised, such as those with HIV, asplenia, or
splenic dysfunction or who respond poorly to the vaccine, such
as people with chronic kidney disease; and those in
immunocompetent risk groups such as patients with chronic
heart, liver, or respiratory disease and people with diabetes.7
The analytical time frame of the study was until 2021 (we
assume that after this time the additional benefits of vaccination
would be negligible). However, we extrapolated the long term
effects of invasive pneumococcal disease over the full lifetime
of the participants in each cohort—that is, until death or 100
years.
Incidence of invasive pneumococcal disease
and mortality risks
Using the most recent data available we estimated age group
and risk group specific incidences. Firstly, we calculated age
specific incidences of invasive pneumococcal disease for the
general population, including cases confirmed by polymerase
chain reaction and culture from the epidemiological year
2009-10 (in this paper we refer to epidemiological years, which
run from July to June, unless stated otherwise).8 These
incidences were subsequently used to estimate the incidence of
invasive pneumococcal disease in high risk people using the
prevalence of clinical risk factors among the general population
and the prevalence among the linked patients admitted to
hospital with invasive pneumococcal disease.7 From the same
databases we estimated the age specific share of meningitis and
empyema to the total invasive pneumococcal disease burden to
allow the inclusion of specific costs related to these outcomes.
We also obtained age group and risk group specific case fatality
ratios for invasive pneumococcal disease from this same study.7
Invasive pneumococcal disease sequelae
Invasive pneumococcal disease may lead to long term sequelae,
especially in the case of meningitis. We obtained the risk of
different types of sequelae from a recent meta-analysis.9 As
patients can have multiple sequelae, we assigned all possible
combinations on the basis of the prevalence of the individual
conditions and reweighted them such that the overall risk to
develop any sequela was equal to the pooled prevalence of
31.7% as estimated by themeta-analysis.We obtained the losses
in overall quality adjusted life years (QALYs) using the most
severe QALY weight in the combination.
Non-bacteraemic pneumococcal pneumonia
To assess whether to include an effect of the 13 valent
pneumococcal conjugate vaccine on non-bacteraemic
pneumococcal pneumonia in the base case we looked at the
impact of the seven valent pneumococcal conjugate vaccine on
the overall incidence of non-bacteraemic pneumonia in high
risk children. For this we obtained the number of episodes of
non-specified pneumonia (ICD J18.X, mentioned in any
diagnostic code) and the number of deaths for the same cases
(within 30 days of admission) for the years 1997-98 up to
2009-10 (data from 2002-03 to 2009-10 were used for deaths)
from the hospital episode statistics database in children aged
less than 5 years. Next, we divided individual cases into risk or
non-risk groups based on the same ICD codes (see appendix 9
in supplementary file) as used for invasive pneumococcal
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disease, and we calculated incidences. An interrupted time series
analysis showed that the incidence of pneumonia requiring
admission to hospital in non-high risk children aged less than
5 years (that is, those eligible for vaccination) was significantly
reduced after the introduction of the seven valent pneumococcal
conjugate vaccine, whereas the incidence in high risk children
of the same age was not significantly reduced (see appendix 1
in supplementary file). Based on the striking difference between
risk and non-risk groups, and the additional uncertainty about
the contribution of Streptococcus pneumoniae to
non-bacteraemic pneumonia, particularly in high risk children,
we decided not to include an overall impact on non-bacteraemic
pneumonia in the base case analysis for the high risk groups.
We did, however, explore the potential impact of including an
effect against non-bacteraemic pneumonia in specific analyses.
For this we used the data on age specific incidence for all cause
pneumonia for the year 2010 from hospital episode statistics
and projected these forward assuming the same incidence as in
2010. Next we assumed that S pneumoniaewould be the causal
agent in 42% of the patients in high risk groups admitted to
hospital with non-bacteraemic pneumonia on the basis of the
results of the twomost recent UK studies available.10 11We then
assumed that the contribution of the vaccine serotypes to
pneumococcal pneumonia would decline in line with the herd
effect of the infant vaccination programme on invasive
pneumococcal disease.
Indirect effects
In virtually all countries the introduction of the seven valent
pneumococcal conjugate vaccine was followed by a large
reduction in invasive pneumococcal disease owing to vaccine
serotypes in vaccinated and unvaccinated age groups, with the
indirect benefits in some age groups partially offset by a
concomitant increase in invasive pneumococcal disease due to
non-vaccine serotypes.4 This was also the case in the United
Kingdom in which the seven valent pneumococcal conjugate
vaccine was introduced in September 2006 with a vaccination
schedule of 2, 4, and 13 months, and catch-up vaccination for
children aged up to 2 years.8 In April 2010, the 13 valent
pneumococcal conjugate vaccine replaced the seven valent
vaccine in the infant vaccination programme.
To predict the future decrease in invasive pneumococcal disease
due to vaccine serotypes in unvaccinated age groups, we divided
the serotypes into those covered by the seven valent vaccine
and those included in the 13 valent vaccine but not in the seven
valent pneumococcal conjugate vaccine. In both cases we used
age group specific (2-4, 5-14, 15-44, 45-64, and >64 years) UK
data on incidence of vaccination before and after the introduction
of the seven valent vaccine. The prevaccination period included
the incidence data for the years 2000-06, whereas the
post-vaccination period included data up to four years after the
introduction of the vaccine (2006-10). Using the age group
specific annual incidence (adjusted for underlying trends in case
ascertainment) we fitted a Poisson regression model adjusting
for the population size to predict the future reduction in cases
of invasive pneumococcal disease due to the vaccine serotypes
(see appendix 2 in supplementary file).
We consequently used the predicted annual decrease in vaccine
serotypes to predict the incidence of the additional serotypes
(except for serotype 3, see below) in the 13 valent vaccine—that
is, we assumed that the herd effects for the additional serotypes
in this vaccine would be similar to those observed for the
serotypes in the seven valent vaccine after the introduction of
the routine infant vaccination programme using the seven valent
pneumococcal conjugate vaccine in 2006.7 The only difference
was that we delayed the herd effects for the six additional
serotypes in the 13 valent vaccine by one year as the introduction
of the vaccination programme using the 13 valent pneumococcal
conjugate vaccine was not combined with a catch-up
programme. This assumption is supported by the most recent
data from the Health Protection Agency, which show no
indication of any herd effect yet in people aged 5 years and
older, 15 months after implementation of the routine infant
vaccination programme using the 13 valent pneumococcal
conjugate vaccine.12 Furthermore, in the Netherlands, where the
vaccination programme using the seven valent pneumococcal
conjugate vaccine was launched without a catch-up, herd effects
were not observed in the first year after implementation in
contrast with the United Kingdom.13
We did not include serotype replacement effect in the model as
we assumed that it would not affect the incremental cost
effectiveness ratio because changes in invasive pneumococcal
disease due to non-vaccine serotypes are expected to be the
same irrespective of the implementation of the risk group
programme.
Vaccine efficacy, number of vaccine doses,
duration of protection
Although the efficacy of the seven valent vaccine in healthy
infants is well established, the available data for risk groups and
adults is scarce, with most studies reporting data on
immunogenicity rather than efficacy.3 Data on the efficacy of
the 13 valent pneumococcal conjugate vaccine is limited12; the
current licence for the use in infants and children from 6 weeks
to 5 years of age and adults aged 50 years and over was based
on immunogenicity rather than efficacy data14 (see appendix 3
in supplementary file for an overview of available data).
Considering the limited data available, we carried out a formal
elicitation of expert opinion on vaccine related variables to
construct a probability distribution that represents the experts’
knowledge and uncertainty.15 The objectives of the elicitation
were to estimate the efficacy of the 13 valent pneumococcal
conjugate vaccine (against invasive pneumococcal disease and
non-bacteraemic pneumococcal pneumonia) and the duration
of protection after one dose of the vaccine (as in the base case
analysis) or two doses of the vaccine. Importantly, recent data
from our group show that the serotype 3 component of the 13
valent pneumococcal conjugate vaccine seems to be ineffective
against invasive pneumococcal disease caused by this serotype.16
Therefore, in the model we also assumed no protection against
disease or carriage for serotype 3.
Specific details on the method of elicitation can be found in
appendix 4 in the supplementary file. Briefly, we asked five
members of the Pneumococcal Subcommittee of the Joint
Committee onVaccination and Immunisation to give an estimate
for the efficacy of the 13 valent pneumococcal conjugate vaccine
in risk groups based on the available efficacy data for the seven
valent pneumococcal conjugate vaccine and immunogenicity
data for both the seven valent and the 13 valent pneumococcal
conjugate vaccines.We used the estimates to create distributions
for vaccine effectiveness using the Sheffield elicitation
framework.15 Final distributions can be found in table 1⇓.
Life years and QALY estimates
As the life expectancy between the general population and high
risk groups differs,17 18 we calculated specific background
mortality for people at high risk (and for the general population
for validating purposes). Data were gathered from the Royal
College of General Practitioners database (including 0.8 million
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patients; more than 1% of the UK population) over a period of
six years (2005 to 2010). We grouped the patients by risk factor
(based on Read codes mapped to ICD-9 codes) and calculated
the number of person years and deaths in the high risk group.
Using these data we calculated background mortality (see
appendix 5 in supplementary file). We also calculated the
mortality for non-risk groups and validated these against life
tables from the Office for National Statistics.19
In addition to life years gainedwe also calculated QALYs gained
by vaccination. For patients admitted to hospital for invasive
pneumococcal disease, we used losses in QALYs of 0.0079 per
case for bacteraemia and 0.0232 per case for meningitis.20 We
assumed that non-bacteraemic pneumococcal pneumonia
resulted in a QALY loss of 0.006 per case.21 In addition to acute
losses in QALYs, we also linked specific losses in QALYs to
the sequelae due to meningitis based on a Dutch study22 (see
table 1 for specific losses in QALYs).
Costs
All costs are reported in pounds sterling at 2009-10 prices.
Where necessary we inflated these using the hospital and
community health services pay and price index.23 As the
perspective was from that of the healthcare provider, we
included only direct costs. We used recommended procedures
to estimate the costs for patients admitted to hospital with
invasive pneumococcal disease. The NHS healthcare resource
group software was used, which combines procedure codes and
ICD-10 diagnostic codes to output the most relevant healthcare
resource group code. We subsequently assigned these codes a
cost from the National Schedule of Reference Costs for NHS
trusts. As the patients included in our analysis are all high risk,
we included only those for which it was likely that the invasive
pneumococcal disease episode was themain cause for admission
to hospital—defined as those patients who had a primary
diagnostic code related to an invasive pneumococcal disease
code (see appendix 6 in supplementary file). Table 1 displays
the costs and probabilities related to invasive pneumococcal
disease. The costs of hospital admission for non-bacteraemic
pneumococcal pneumonia were based on reference costs for
pneumonia. We used the weighted average costs based on the
number of non-elective admissions for pneumonia without
complications (NHS reference costs codeWADZ11C). Patients
who had meningitis without sequelae were assumed to have a
single outpatient appointment after discharge; we obtained the
cost of treatment and care for patients with sequelae after
meningitis from a previous cost effectiveness analysis.24
The total cost per dose of 13 valent pneumococcal conjugate
vaccine was estimated at £56.61, consisting of the price of the
vaccine (£49.10) and administration costs (£7.51).
Scenario and sensitivity analysis
We carried out univariate, threshold, scenario, and probabilistic
sensitivity analyses. In the univariate sensitivity analyses,
relevant variables were based on the 5% and 95% quantiles to
explore the impact of uncertainty around each variable. A
threshold analysis was done in which we varied the vaccine
price to investigate the effect on the incremental cost
effectiveness ratio.
In specific scenario analyses we explored the impact of changes
in vaccine efficacy, vaccine waning, delaying the herd effect of
the infant vaccination programme using the 13 valent
pneumococcal conjugate vaccine, assuming life expectancy of
the general population (rather than using the life expectancy of
people in high risk groups), and the effect of discounting.
For the probabilistic sensitivity analyses, we generated variables
using Monte Carlo sampling, with outcome values generated
by running the model 5000 times using Latin hypercube
sampling. When quantitative data about uncertainty around
variables were available we used log normal and β distributions
(see table 1 for specific distributions). When only a single point
estimate was available, we assumed a normal distribution with
a coefficient of variation of 0.25. For all the sensitivity analyses
it was assumed that the vaccination programme would be
launched in 2012-13 (two to three years after the infant
programme).
Outcome measures and cost effectiveness
analysis
The simulation model tracks the incidence of invasive
pneumococcal disease and non-bacteraemic pneumococcal
pneumonia, the number of deaths, costs, QALYs, and life years.
We calculated the net costs, life years gained, and QALYs by
summing all the costs, life years, and QALYs and calculating
the differences for the evaluations with and without vaccination.
The incremental cost effectiveness ratio was calculated by
dividing the net costs by either the life years gained or QALYs
gained. Health effects and cost were both discounted at 3.5%
according to the UK guidelines.25 In the analyses we compared
the possible impact of vaccination using the 13 valent
pneumococcal conjugate vaccine with that of the current
situation. Currently, adults aged more than 65 years and people
in at risk groups aged 2 years or more are recommended to be
vaccinated with the 23 valent polysaccharide vaccine26; however,
uptake of the vaccine is relatively low, especially in those aged
less than 65 years (see appendix 7 in supplementary file).7 We
assumed that the 13 valent pneumococcal conjugate vaccine,
would be used in addition to the 23 valent polysaccharide
vaccine.
Finally, we assumed that the uptake of the 13 valent
pneumococcal conjugate vaccine would be similar to the annual
influenza programme in the United Kingdom, at 34.5% in the
age group 2-16, 53.6% in the age group 16-65, and 72.4% in
the age group 65 and older27 and that vaccination with the 13
valent pneumococcal conjugate vaccine would be offered
irrespective of previous vaccination with the 23 valent
polysaccharide vaccine.
Results
Incidence of invasive pneumococcal disease,
vaccine efficacy, indirect effects, and life
expectancy
Among high risk groups the highest incidence of invasive
pneumococcal disease was in young people infected with HIV
and the lowest in those with chronic heart disease, diabetes, or
splenic dysfunction (see appendix 8 in supplementary file for
estimated incidence of invasive pneumococcal disease among
high risk groups). Table 1 shows the estimates for vaccine
efficacy based on the elicitation of expert opinion and the
estimated costs associated with different types of invasive
pneumococcal disease. Appendix 2 in the supplementary file
presents the Poisson regression for invasive pneumococcal
disease due to vaccine serotypes after the introduction of the
seven valent pneumococcal conjugate vaccine. Finally, appendix
5 in the supplementary file shows the life expectancy for people
in high risk groups.
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Total burden in high risk groups
Without a vaccination programme based on risk groups, but
taking into account the likely herd effects of the infant
vaccination programme using the 13 valent pneumococcal
conjugate vaccine, the model predicts that from 2012-13 to
2020-21 about 1333 cases of invasive pneumococcal disease
due to vaccine serotypes would occur in people at high risk
(table 2⇓). This corresponds to a total loss of about 5900 life
years or 6200 QALYs (undiscounted). The herd impact of the
infant vaccination programme using the 13 valent pneumococcal
conjugate vaccine is large; preventing an additional 6200
invasive pneumococcal disease cases due to vaccine serotypes
corresponding to an additional 30 400 QALYs lost compared
with a continuing infant vaccination programme using the seven
valent pneumococcal conjugate vaccine.
Impact on budgets
A risk based vaccination programme would require 4.1 million
vaccine doses (assuming the same vaccine uptake as the annual
influenza vaccination programme), resulting in a total cost of
around £233m (of which £202m is attributed to the vaccine and
the remainder to administration costs). Focusing on specific
high risk groups, in whom vaccination would be most cost
effective, could reduce the costs substantially. For example,
vaccinating people with chronic liver disease would result in a
total net cost of £4.6m. Furthermore, table 3⇓ also shows the
impact on budgets of assuming a higher coverage among all
risk groups (80% uptake) and the impact assuming the same
annual coverage as for the 23 valent polysaccharide vaccine
(see appendix 7 in supplementary file). If coverage is no higher
than that achieved by the 23 valent vaccine, then the impact on
budgets would be much reduced, as this programme only
achieves poor levels of uptake.
Cost effectiveness
The base case analysis (excluding a possible impact against
non-bacteraemic pneumococcal pneumonia) assumed it would
be possible to start vaccinating at risk groups in the
epidemiological year 2012-13. Using a threshold of £30 000
for a willingness to pay for a QALY gained,25 only vaccination
of patients with chronic liver disease (table 4⇓) would be deemed
cost effective. People infected with HIV was the second most
favourable at risk group, with an incremental cost effectiveness
ratio of £61 200 per QALY gained. Vaccinating all other at risk
groups would not be considered cost effective, with an
incremental cost effectiveness ratio of more than £80 000 per
QALY gained.
Impact of time on cost effectiveness
The expected indirect benefits as a result of the infant
vaccination programme limit the direct effect of targeting high
risk groups. As a result the cost effectiveness of vaccinating at
risk groups decreases over time as indirect benefits accrue. If a
programme targeted at high risk groups had been initiated in
2009-10, then vaccinating immune compromised people and
people with chronic respiratory disease and HIV infection could
also be deemed cost effective (incremental cost effectiveness
ratio of ≤£30 000 per QALY). Figure 1⇓ shows the impact of
time on the incremental cost effectiveness ratio for the years
2009-10 up to 2015-16.
Sensitivity analyses
Table 4 shows the impact on the incremental cost effectiveness
ratio of assuming an overall impact on non-bacteraemic
pneumonia. If included, even vaccinating the whole group at
increased risk of invasive pneumococcal disease might be
considered cost effective, with an incremental cost effectiveness
ratio of £17 500 per QALY. Figure 2⇓ shows the maximum
costs of vaccination for it to be considered cost effective. These
costs will decrease with a decreasing net effect of the vaccine
in time. In the base case (no overall impact on non-bacteraemic
pneumonia) the vaccine costs have to be reduced for all risk
groups, except for patients with chronic liver disease, to consider
a risk group programme to be cost effective.
The results of the scenario analyses (table 5⇓) and the univariate
sensitivity analysis (fig 3⇓) show that the predicted herd effects
of the infant programme and vaccine efficacy have a large
impact on the incremental cost effectiveness ratios. For instance,
if there are no herd effects resulting from the additional types
now included in the infant vaccination programme then the cost
effectiveness of targeting all high risk groups would be reduced
from over £180 000 to around £47 000 per QALY gained. Other
important factors were the price of the vaccine, the risk and age
group specific incidence, and the case fatality ratio. Also, the
scenario analysis showed that the additional benefits of a second
dose were outweighed by the doubling of the costs.
Probabilistic sensitivity analysis
Figure 4⇓ shows the cost effectiveness acceptability curves for
the risk groups in whom the incremental cost effectiveness ratio
was less than £100 000 per QALY. It is clear that if the vaccine
does not offer protection against non-bacteraemic pneumococcal
pneumonia then only vaccinating patients with chronic liver
disease is likely to be considered cost effective, but by assuming
an overall impact against non-bacteraemic pneumococcal
pneumonia, vaccinating any of the at risk groups would probably
be cost effective.
Discussion
Although the herd effects of the infant vaccination programme
using the 13 valent pneumococcal conjugate vaccine will in
time indirectly protect people at high risk, the burden of
preventable pneumococcal disease will remain high during the
first years after the introduction of the vaccination programme.
Vaccinating all groups at high risk of invasive pneumococcal
disease with the 13 valent pneumococcal conjugate vaccine
would have a large impact on budgets, therefore targeting
specific high risk groups may be more attractive although this
would require general practitioners to identify subgroups among
those at increased risk. Our analysis shows that unless the 13
valent pneumococcal conjugate vaccine also offers protection
against non-bacteraemic pneumococcal pneumonia, vaccination
is unlikely to be considered cost effective for most at risk groups.
The assumptions about vaccine efficacy and effectiveness, and
in particular that against non-bacteraemic pneumococcal
pneumonia, had a large impact on our results, and a great deal
of uncertainty surrounds these estimates. Although evidence
from randomised controlled trials would be preferable to expert
opinion, by the time results are available28 the potential benefits
of vaccinating high risk groups are already largely limited by
the expected herd effects.
Strength and weaknesses of the study
This is the first economic evaluation of vaccination against
pneumococcal disease in specific high risk groups using the 13
valent pneumococcal conjugate vaccine. The two most
influential variables on the outcome were the assumed herd
protection benefits from the infant pneumococcal vaccination
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programme and the vaccine effectiveness against
non-bacteraemic pneumococcal pneumonia.
Dynamic models have been used to predict the herd effects of
the infant vaccination programme but their reliability critically
depends on the structure and underlying assumptions, such as
vaccination coverage, difference in case-carrier ratios between
serotypes, and the level of competition between vaccine
serotypes and non-vaccine serotypes in carriage.18 29 Hence any
such model predictions are subject to considerable uncertainty.
Therefore we decided to predict the future herd effects by using
Poisson regression models, assuming that the decrease in the
additional serotypes (with the exception of serotype 3) would
be similar to those observed after the introduction of the seven
valent pneumococcal conjugate vaccine. Nevertheless, the herd
effect for the six additional serotypes in the 13 valent
pneumococcal conjugate vaccine might be different from those
in the seven valent vaccine owing to differences in carriage,
transmissibility, and the potential to cause disease.30 31 We also
assumed that the herd effects would be similar among high risk
and non-high risk groups, as this was previously also observed
for invasive pneumococcal disease due to serotypes in the seven
valent pneumococcal conjugate vaccine.7 However, as the less
invasive serotypes primarily affect people at high risk and the
additional serotypes included in the 13 valent pneumococcal
conjugate vaccine are the more invasive, people at high risk
might benefit less from herd effects compared with healthy
people.32 This may also explain the failure to find a reduction
in non-bacteraemic pneumonia in children at high risk compared
with healthy children.
Another key assumption was the vaccine efficacy against
invasive pneumococcal disease and non-bacteraemic
pneumococcal pneumonia. The main reason for not including
an effect against non-bacteraemic pneumococcal pneumonia in
the base case analysis was that the time series analysis did not
show any measurable effect on admissions due to pneumonia
in high risk children eligible for vaccination with the seven
valent pneumococcal conjugate vaccine, whereas a significant
reduction was observed in non-high risk children of the same
age. This might be explained by different pathogens (viral or
bacterial) causing pneumonia in high risk populations and for
those with pneumococcal pneumonia, a different serotype
distribution in high risk compared with low risk people. As we
had the ability to analyse our surveillance data by whether
patients had comorbidities, which would seem essential for
deciding on a risk based vaccination programme, our assumption
of the effectiveness against non-bacteraemic pneumonia differs
from two previous analyses.33 34 We do, however, also note that
the effect of being in an at risk group on increasing the risk of
invasive pneumococcal disease is more noticeable in children
than in adults,7 which might mean that our assumption of lack
of a direct effect of the 13 valent pneumococcal conjugate
vaccine on non-bacteraemic pneumonia in adults may be
conservative,5 yet consistent with the BMJ guidelines for
economic evaluations.7 35
Finally, we note that the impact of non-bacteraemic
pneumococcal pneumonia was high in our analysis despite a
relatively low vaccine efficacy being used in combination with
a relatively high waning rate (table 1).
The cost effectiveness of vaccination depends heavily on the
probability of developing disease. In our analysis this was based
on the observed odds of invasive pneumococcal disease in risk
groups compared with those not in risk groups and the absolute
incidence of non-risk group related disease. One of the caveats
of the risk factor study was that patients were attributed to risk
groups on the basis of the presence of specific discharge codes.
Some of the risk groups might not have been consistently
recorded. The odds for people with asplenia were low in the
study, with no obvious increased probability of developing
disease, resulting in unfavourable incremental cost effectiveness
ratios. Although this might be explained by successful
prophylaxis by antibiotics or polysaccharide vaccine, it is
possible that people with asplenia were poorly recorded.
Therefore the cost effectiveness of some of the described risk
groups might have been underestimated, although sensitivity
analyses showed that our conclusions remained valid when we
increased the incidence. Also, the future incidence of
pneumococcal disease due to vaccine serotypes may be affected
by changes in the epidemiology of viral respiratory tract
infections, such as happened with pandemic A/H1N1 2009
influenza.36 This caused a noticeable increase in invasive
pneumococcal disease in the age groups with the highest
incidence of H1N1 infection,36 and, given the overlap between
the risk groups for influenza and invasive pneumococcal disease,
selective vaccination of high risk groups with the 13 valent
pneumococcal conjugate vaccine might help mitigate the effects
of future increases in such viral infections.
Comparison with other studies
This is the first cost effectiveness analysis of the 13 valent
pneumococcal conjugate vaccine focusing specifically on people
at increased risk for invasive pneumococcal disease. As far as
we know, two other studies have focused on the cost
effectiveness of vaccinating non-infant populations.33 34Amain
difference is that these studies focused on older adults (>50
years34 and 6533 years), whereas our study specifically focused
on risk groups of people aged 2 years and older. Both these
studies showed that for these specific age groups a vaccination
programme could be considered cost effective, whereas we in
the base-case analysis conclude that a vaccination programme
in unlikely to be considered cost effective. The main driver for
this difference is that in the base case analysis we assumed that
the 13 valent pneumococcal conjugate vaccine would not have
an overall impact on non-bacteraemic pneumonia. This
difference was further driven by the assumption that vaccine
would not be effective against serotype 3, as early data from
England andWales suggests that this component of the 13 valent
vaccine does not seem to provide direct protection to vaccinated
people.16 However, this assumption was based on a few cases
of invasive disease due to this serotype in children in England
and Wales and future data are necessary to answer the
outstanding question on the efficacy of this serotype.
Other differences between our study and these two age based
studies are that we had detailed data on the risk of disease, the
life expectancy of high risk populations, and specific costs per
invasive pneumococcal disease episode available, all based on
primary data as opposed to estimates from the literature or
databases. Furthermore, compared with the Dutch study we
were able to explicitly take herd effects into account for the
unvaccinated population as recent data has become available
that could be used for the prediction of these effects.8
We showed in the current study that these herd effects have a
major impact on cost effectiveness. It is desirable that specific
cost effectiveness studies from a European perspective become
available to guide decision making in European countries rather
than using cost effectiveness estimates from the United States.
Previous decisions to introduce the infant pneumococcal
vaccination programmes in European countries largely relied
on herd immunity estimates from the United States that were
subsequently shown not to be applicable elsewhere.3
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Implications and future research
We found that the cost effectiveness of the 13 valent
pneumococcal conjugate vaccine programme based on risk
group will mainly depend on the time of using the vaccine and
its effectiveness, in particular against non-bacteraemic
pneumococcal pneumonia. Since most countries have replaced
the seven valent pneumococcal conjugate vaccine with the 13
valent vaccine, herd effects are likely to decrease the burden of
preventable pneumococcal disease over time rendering any
additional preventive efforts less cost effective. If the 13 valent
vaccine does protect against non-bacteraemic pneumococcal
pneumonia in high risk groups the programme may be cost
effective if introduced early enough before the full effect of
herd immunity is manifested, or if the expected herd immunity
effect is less than expected. Policy makers may prefer to delay
any decision about the use of the 13 valent vaccine in high risk
groups until the results of the trial currently being done in the
Netherlands to assess its efficacy against non-bacteraemic
pneumonia in elderly people are available.28 However, such a
wait and see policy would possibly reduce the need for the
additional vaccination effort. Another option for governments
to consider would be sharing the risk with the manufacturer; on
the basis of the uncertainty around the cost effectiveness a price
reduction could be negotiated that remains valid until the data
on efficacy become available. The implementation of a risk
based vaccination programme using the 13 valent pneumococcal
conjugate vaccine in the United Kingdom has been considered
by the UK Joint Committee on Vaccination and Immunisation,
with the final decision being not to introduce such a programme
largely dependent on the outcome of our study.37Asmany other
European countries lack the various high quality epidemiological
data sources available in the United Kingdom or lack the
statistical power owing to their population size to conduct their
own analyses this study will also provide them with important
evidence. Specific cost effectiveness ratios cannot directly be
extrapolated from England to other countries but we believe
that the general conclusion is informative for those countries
that introduced the 13 valent pneumococcal conjugate vaccine
around the same time and have a similar uptake of vaccination.
Some European countries are, however, already recommending
the 13 valent pneumococcal conjugate vaccine for at risk groups
or adults. For example, in Austria and Greece the 13 valent
pneumococcal conjugate vaccine is recommended for those
aged 50 and older,38 39 whereas in France, parts of Germany,
and Italy the vaccine is being recommended for (specific) risk
groups.40 41
Finally, we note that in addition to considerations about cost
effectiveness, decision makers need to estimate carefully the
possible uptake of vaccination, considering the potentially large
impact on budgets of a risk based vaccination programme using
the 13 valent pneumococcal conjugate vaccine.
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Table 1| Variables used in economic model
ReferenceDistributionExpected valueVariables
See methodsNASee appendix 8 in supplementary
file
Age specific incidence
7, see methodsLog normalAge and risk group dependent*Odds of IPD*
7, see methodsβAge and risk group dependent†Case fatality ratio†
See methodsFixed3-8% (age dependent)Share of meningitis in total burden of IPD
See methodsFixed1-5% (age dependent)Share of empyema in total burden of IPD
Vaccine efficacy against IPD‡
High risk immunocompetent:
See methodsβ (α 2.1, β 0.863)0.71<65 years
See methodsβ (α 2.01, β 1.19)0.63≥65 years
High risk immunocompromised:
See methodsβ (α 1.59, β 1.41)0.53<65 years
See methodsβ (α 1.21, β 1.62)0.43≥65 years
Vaccine efficacy against non-bacteraemic pneumococcal pneumonia‡
High risk immunocompetent:
See methodsβ (α 1.88, β 2.19)0.46<65 years
See methodsβ (α 1.47, β 2.2)0.40≥65 years
High risk immunocompromised:
See methodsβ (α 1.24, β 2.55)0.33<65 years
See methodsβ (α 1.27, β 3.47)0.27≥65 years
Waning immunity (per year)§
Immunocompetent:
See methodsSee methods0.11<65 years
See methodsSee methods0.25≥65 years
Immunocompromised:
See methodsSee methods0.24<65 years
See methodsSee methods0.26≥65 years
Prevalence of sequelae after meningitis
9β (mean 0.08 SE 0.03)0.08Deafness
9β (mean 0.21 SE 0.02)0.21Mild hearing loss
9β (mean 0.07 SE 0.02)0.07Seizures and hydrocephalus
9β (mean 0.09 SE 0.01)0.09Spasticity or paresis
9β (mean 0.12 SE 0.04)0.12Cranial nerve palsy
Quality adjusted life year losses
21 20β (mean 0.023 SE 0.031)0.023Hospital admission for meningitis
21β (mean 0.079 SE 0.083)0.0079Hospital admission for bacteraemia¶
21 20Normal (mean 0.006 SD 0.0015)0.006Hospital admission for non-bacteraemic pneumonia
Quality of life weights
22β (mean 0.81 SE 0. 028)0.81Deafness
22β (mean 0.91 SE 0.015)0.91Mild hearing loss
22β (mean 0.83 SE 0.015)0.83Seizures
22β (mean 0.62 SE 0.021)0.62Hydrocephalus
22β (mean 0.67 SE 0.023)0.67Spasticity or paresis
22β (mean 0.67 SE 0.023)0.67Cranial nerve palsy
Costs (£)
See methodsNormal (mean 6509 SD 405)6509Case of meningitis**
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See methodsNormal (mean 7665 SD 444)7538Case of empyema**
See methodsNormal (mean 839 SD 3.93)825Short hospital stay for other IPD**
Long hospital stay for other IPD:
See methodsNormal (mean 9129 SD 142)8977With excess days in hospital**
See methodsNormal (mean 3073 SD 19)3022Without excess days in hospital**
See methodsNormal (mean 672 SD 168)661Admitted to hospital for pneumonia
See methodsβ (α 5075 β 8257)0.61Chance of long stay for IPD
See methodsβ (α 2328 β 5075)0.46Chance of excess days during long stay for IPD
Lifetime costs after meningitis:
24Log normal (mean 8.7 SD 0.4)6591In first year
24Log normal (mean 8.7 SD 0.4)203In subsequent years
24Log normal (mean 5.2 SD 0.4)382Outpatient follow-up for meningitis
42Fixed49.10Cost of 13 valent pneumococcal conjugate vaccine
42Fixed7.51Administration costs
Other variables
See appendix 2 in supplementary
file
NormalSee appendix 2 in supplementary
file
Herd effect due to infant vaccination
See methodsNASee appendix 2 in supplementary
file
Life expectancy among high risk groups
25NA3.5%Discount rate for costs and health effects
IPD=invasive pneumococcal disease; £1.00 ($1.6; €1.2).
*Odds ratio of IPD comparing risk groups to non-risk groups. Specific odds ratios can be found in Van Hoek et al.7
†Age specific case fatality ratios can be found in Van Hoek et al.7
‡After single dose during first year of vaccination. Efficacy estimates do not apply for serotype 3 (see method section).16 Estimates of vaccine efficacy after two
doses are listed in appendix 4 in the supplementary file.
§Annual waning factor was calculated by using the experts’ estimation of vaccine efficacy during first and third year after vaccination using annual exponential
decay of immunity.
¶Same quality of life year decrement was assumed for invasive pneumonia, bacteraemia with focus, and bacteraemia without focus.
**Mean costs were sampled from a normal distribution with a mean equal to the log normal mean and standard deviation equal to the standard error of the log
normal mean.
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Table 2| Total burden of invasive pneumococcal disease (IPD) due to vaccine serotype (undiscounted) over nine year period (2012-13 to
2020-21) in people at high risk
QALYsLife yearsDeaths
Cases of IPD due to
vaccine serotypesVariables
36 57934 25118957522Without high risk vaccination and without herd protection benefits of 13 valent pneumococcal conjugate
vaccine*
30 38228 39715386189Cases prevented by herd effects of infant 13 valent pneumococcal conjugate vaccine programme†
619758543571333Without high risk vaccination and with herd effects of additional six serotypes in 13 valent pneumococcal
conjugate vaccine
42744033247927With high risk group vaccination (including herd effects of infant programme)‡
19231821110406Averted burden by high risk vaccination (incremental effects)§
QALYs=quality adjusted life years.
*Only including herd effect due to serotypes included in seven valent pneumococcal conjugate vaccine
(excluding herd effect due to six additional serotypes included in 13 valent pneumococcal conjugate vaccine.
†Herd effects due to additional six serotypes in 13 valent pneumococcal conjugate vaccine based on
incidence after vaccination with seven valent pneumococcal conjugate vaccine (see methods and appendix
2 in supplementary file).
‡Vaccination uptake to be assumed similar to that of annual influenza uptake (see methods).
§Numbers may not add up owing to rounding.
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Similar to annual 23 valent
polysaccharide vaccination programme†80%












*Annual influenza coverage 34.5% in 2-15 year olds, 53.6% in 16-65 year olds, and 72.4% in those aged ≥65 years.27 Sum of costs of separate risk groups are
higher than total costs of any risk group as people may have more than one underlying condition.
†Annual uptake 4.1% in 2-15 year olds, 1.5% in 16-65 year olds, and 7.2% in those aged ≥65 years). See appendix 7 in supplementary file.
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Table 4| Incremental cost effectiveness ratios (ICERs) in £/quality adjusted life year (QALY) per risk group assuming vaccination will be





17 503183 680Any risk group
37 6861 204 091Splenic dysfunction
14 83290 243Chronic respiratory disease
16 043161 063Chronic heart disease
22 641493 682Chronic kidney disease
10 82520 324Chronic liver disease
18 459269 750Diabetes
24 29690 720Immunocompromised
28 14461 239Infected with HIV†
£1.00 ($1.6; €1.2).
*Assuming no overall impact on non-bacteraemic pneumonia in high risk group.
†When the assumption was made that life expectancy of people infected with HIV would be similar to high risk immonocompetent people,43 44 incremental cost
effectiveness ratios were estimated at £54 409/QALY in base case analysis and at £25 717/QALY when an effect against non-bacteraemic pneumococcal pneumonia
was included.
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Table 5| Result of scenario analyses on incremental cost effectiveness ratio (£/quality adjusted life year, QALY) for those risk groups that
had an incremental cost effectiveness ratio (ICER) <100 000 per QALY in base case for epidemiological year 2012-13
Infected with HIVImmunocompromisedChronic liver disease
Chronic respiratory
diseaseAny risk groupVariables
61 23990 72020 32490 243183 680Base case
10 05920 059284818 06137 687No herd effects due to any serotypes in
13 valent pneumococcal conjugate
vaccine*
12 40425 259352922 71546 903No herd effects due to six additional
serotypes in 13 valent pneumococcal
conjugate vaccine†
25 18141 115649636 12274 882No herd effects due to serotypes 1 and
5†
39 45263 30113 36963 257128 603Herd effect of infant 13 valent
pneumococcal conjugate vaccine delayed
by two years
47 34270 72015 77270 390143 564Vaccine price 25% reduced
38 84058 48412 98758 244119 021Vaccine price 25% reduced and no
administration costs
45 18165 10717 01369 927141 999No waning immunity
34 48459 73011 57060 164120 495No discounting
50 33181 03618 44679 937163 070Life expectancy of normal population
97 066143 58134 429153 053308 886Double vaccine dose
52 88078 69117 58678 302159 55015% higher incidence of invasive
pneumococcal disease
54 09974 09917 62073 331150 326Assuming 13 valent pneumococcal
conjugate vaccine to be effective against
serotype 3
*No further reduction as from 2009-10 for all serotypes included in 13 valent pneumococcal conjugate vaccine.
†20% less herd effects could be achieved when serotypes 1 and 5 were not assumed to provide herd protection and 80% less herd effects could be achieved
when six additional serotypes included in 13 valent pneumococcal conjugate vaccine would not provide any herd effect compared with maximum herd effect (for
example, total eradication of all serotypes included in 13 valent pneumococcal conjugate vaccine) calculated by using specific incidence data on serotype for
2009-10 and projecting forward.
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Fig 1 Impact of time on incremental cost effectiveness ratio. QALY=quality adjusted life year
Fig 2 Maximum costs per vaccinee (including costs of vaccine and administration) to consider risk group vaccination cost
effective (incremental cost effectiveness ratio of ≤£30 000 per quality adjusted life year)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e6879 doi: 10.1136/bmj.e6879 (Published 26 October 2012) Page 15 of 17
RESEARCH
 on 22 O












J: first published as 10.1136/bm





Fig 3 Univariate sensitivity analysis for any at risk group. Variables were changed over their 5% and 95% quantiles, with
exception of share of meningitis and empyema, which were varied by 50%. Incidence was altered by varying odds of
invasive pneumococcal disease in those with risk factors compared with those without. Bar for lower vaccine efficacy are
cut-off for all at risk groups except immunocompromised patients. Please note that the scales of the figures vary. QALY=quality
adjusted life year
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Fig 4 Results of probabilistic sensitivity analysis
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